Evidence map›Paper›PMID 42056941›Full record

ArticleBMC cancer2026

Clinical characteristics and prognosis of therapy-related acute myeloid leukemia patients with RUNX1::RUNX1T1.

Yu-Han Chang, Guang-Hui Chang, Hai-Tao Gao, Qiang Fu, Xiao-Su Zhao, Ya-Zhen Qin, Qian Jiang, Hao Jiang, Lan-Ping Xu, Yu Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yu-Han Chang *Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Guang-Hui Chang *Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Hai-Tao GaoBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Qiang FuBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Xiao-Su ZhaoBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Ya-Zhen QinBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Qian JiangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Hao JiangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Lan-Ping XuBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Yu WangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Xiao-Hui ZhangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Xiao-Jun HuangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Fei-Fei TangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. bjmugirl@163.com.

Funding

Beijing Research Ward Excellence Program BRWEP2024W134080106Peking University Medicine Fund for world's leading discipline or discipline cluster development 71003Y3035
6 · The paper itself

Abstract

backgroundThis study aimed to analyze the clinical characteristics and prognostic factors in therapy-related acute myeloid leukemia (t-AML) patients with RUNX1::RUNX1T1 fusion.

methodsA retrospective analysis was performed. Twenty-three t-AML patients with RUNX1::RUNX1T1 were included as the case group. Ninety-two de novo AML patients with RUNX1::RUNX1T1 were randomly selected using the case-pair method in a 1:4 ratio who matched for (1) sex, (2) age (± 5 years), (3) time of diagnosis (± 3 years). A total of 115 AML patients with RUNX1::RUNX1T1 were enrolled.

resultsThe CR rate after two cycles in t-AML patients with RUNX1::RUNX1T1 was same to that in de novo AML patients with RUNX1::RUNX1T1(95.6% vs. 95.6%, p = 0.48). Survival analysis indicated the 3-year overall survival (OS) of t-AML and de novo AML patients with RUNX1::RUNX1T1 were 68.2% vs. 83.1% (P = 0.23), and 3-year disease-free survival (DFS) were 60.9% vs. 65.3% (P = 0.84). Multivariate analysis demonstrated that age ≥ 60 years, CCND3, DNMT3A and FLT3 mutation were independent adverse factors, but achieving MMR after three cycles were independent favorable factors for survival of AML patients with RUNX1::RUNX1T1.

conclusionsThis study showed no significant differences in remission rates and survival between the two groups. Multivariate analysis demonstrated that age ≥ 60 years, CCND3, DNMT3A and FLT3 mutation were independent adverse factors, but achieving MMR after three cycles were independent favorable factors for survival.

Indexed as

Core Binding Factor Alpha 2 SubunitLeukemia, Myeloid, AcuteOncogene Proteins, FusionRUNX1 Translocation Partner 1 ProteinAdolescentAdultAgedDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesYoung AdultCore Binding Factor Alpha 2 SubunitDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanOncogene Proteins, FusionRUNX1 protein, humanRUNX1T1 protein, humanRUNX1 Translocation Partner 1 ProteinNGSRUNX1:RUNX1T1t-AML

Identifiers

PMID42056941
PMCPMC13270916

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.